Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines” (Annals of Oncology (2018) 29(S4) (iv96–iv110), (S0923753419316886), (10.1093/annonc/mdx758));Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Annals of Oncology

Volumn 29, Issue , 2018, Pages iv96-iv110

  Aapro, M ^a   Beguin, Y ^b,c   Bokemeyer, C ^d   Dicato, M ^e   Gascon P ^f   Glaspy, J ^g   Hofmann, A ^h   Link, H ⁱ   Littlewood, T ^j   Ludwig, H ^k   Osterborg A ^l   Pronzato, P ^m   Santini, V ⁿ   Schrijvers, D ^o   Stauder, R ^p   Jordan, K ^q   Herrstedt, J ^r,s  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF HAMBURG   (Germany)

^e CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Medical Society for Blood Management   (Austria)

ⁱ Westpfalz Klinikum GmbH   (Germany)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^k WILHELMINEN HOSPITAL   (Austria)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o ZiekenhuisNetwerk Antwerpen   (Belgium)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^s UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; ERYTHROPOIETIN RECEPTOR; IRON; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COMORBIDITY; DISEASE ASSESSMENT; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; IRON DEFICIENCY; IRON STATUS ASSESSMENT; LONG TERM CARE; MALIGNANT NEOPLASM; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT INDICATION; ADVERSE EVENT; BLOOD; COMPLICATION; EUROPE; EXPERIMENTAL THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IRON DEFICIENCY ANEMIA; MEDICAL SOCIETY; NEOPLASM; ONCOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; ERYTHROCYTE TRANSFUSION; EUROPE; HEMATINICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON; MEDICAL ONCOLOGY; NEOPLASMS; SOCIETIES, MEDICAL; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 85053046352     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy323     Document Type: Erratum

References (165)

1. Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
2. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013; 24: 1886-1892.
3. Delarue R, Tilly H, Salles GA et al. Iron parameters and relation to prognosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study. Blood 2013; 122 (Abstr 2202).
4. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
5. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979-986.
6. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
7. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001; 84(Suppl 1): 31-37.
8. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-2221.
9. Hudis CA, Van Belle S, Chang J, Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. Oncologist 2004; 9(Suppl 5): 55-69.
10. Aapro M, österborg A, Gascón P et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol 2012; 23: 1954-1962.
11. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia-v. 1. 2018, 2017; http://www. nccn. org/professionals/physician-gls/PDF/anemia. pdf (18 October 2017, date last accessed).
12. Aapro M, Chernov VM, Gladkov OA et al. Practical recommendations for the treatment of anemia in cancer patients. Malignant Tumors 2016; 4(Special Issue 2): 368-377.
13. Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045-4059.
14. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011; 16(Suppl 3): 35-42.
15. Malcovati L, Hellström-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964.
16. Efficace F, Gaidano G, Breccia M et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2015; 168: 361-370.
17. de Swart L, Smith A, Johnston TW et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol 2015; 170: 372-383.
18. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21(Suppl 5): v244-v247.
19. Bokemeyer C, Aapro M, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
20. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13(Suppl 3): 33-36.
21. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106: 1249-1258.
22. Fenaux P, Haase D, Sanz GF et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii57-iii69.
23. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
24. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-timesweekly dosing. J Clin Oncol 2001; 19: 2875-2882.
25. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
26. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
27. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
28. Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. Oncologist 2009; 14(Suppl 1): 1-5.
29. Tonia T, Mettler A, Robert N et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407.
30. Bohlius J, Tonia T, Nüesch E et al. Effects of erythropoiesis-stimulating agents on fatigue-and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 2014; 111: 33-45.
31. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446-4453.
32. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
33. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 3: CD007303.
34. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
35. Hoff CM, Hansen HS, OvergaardMet al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy-results from the randomized DAHANCA 5 study. Radiother Oncol 2011; 98: 28-33.
36. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
37. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-1050.
38. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-1032.
39. Leyland-Jones B, Bondarenko I, Nemsadze G et al. A randomized, open-label, multicenter, phase III study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy. J Clin Oncol 2016; 34: 1197-1207.
40. Engert A, Josting A, Haverkamp H et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010; 28: 2239-2245.
41. Moebus V, Jackisch C, Schneeweiss A et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Nat Cancer Inst 2013; 105: 1018-1026.
42. Pirker R, Ramlau RA, Schuette W et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008; 26: 2342-2349.
43. Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009; 101: 1961-1971.
44. Aapro M, Moebus V, Nitz U et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a metaanalysis. Ann Oncol 2015; 26: 688-695.
45. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315.
46. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-2847.
47. Vansteenkiste J, Glaspy J, Henry D et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: studylevel and patient-level meta-analyses. Lung Cancer 2012; 76: 478-485.
48. Hershman DL, Buono DL, Malin J et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-1641.
49. National Institute for Health and Care Excellence (NICE). 2014. Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142). www. nice. org. uk/guidance/ta323 (23 February 2015, date last accessed).
50. Henke M, Mattern D, PepeMet al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-4713.
51. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
52. Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110: 477-488.
53. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-3565.
54. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115: 4254-4263.
55. Brown WM, Maxwell P, Graham AN et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007; 25: 718-722.
56. Elliott S, Busse L, Bass MB et al. Anti-epo receptor antibodies do not predict epo receptor expression. Blood 2006; 107: 1892-1895.
57. Elliott S, Busse L, McCaffery I et al. Identification of a sensitive antierythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 2010; 352: 126-139.
58. Elliott S, Swift S, Busse L et al. Epo receptors are not detectable in primary human tumor tissue samples. PLoS One 2013; 8: e68083.
59. Elliott S, Sinclair A, Collins H et al. Progress in detecting cell-surface protein receptors: the erythropoietin receptor example. Ann Hematol 2014; 93: 181-192.
60. Liang K, Esteva FJ, Albarracin C et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18: 423-435.
61. Cao Y, Lathia JD, Eyler CE et al. Erythropoietin receptor signaling through stat3 is required for glioma stem cell maintenance. Genes Cancer 2010; 1: 50-61.
62. Kumar SM, Zhang G, Bastian BC et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 2012; 31: 1649-1660.
63. Wu P, Zhang N, Wang X et al. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. PLoS One 2012; 7: e45122.
64. Osterborg A, Aapro M, Cornes P et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007; 43: 510-519.
65. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009; 123: 679-686.
66. Zonder JA. Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006: 348-355.
67. Galli M, Elice F, Crippa C et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004; 89: 1141-1142.
68. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
69. Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi85-vi92.
70. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Cancer-Associated Venous Thromboembolic Disease-v. 1. 2017, 2017; http://www. nccn. org/professionals/physician-gls/pdf/ vte. pdf (18 October 2017, date last accessed).
71. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33: 654-656.
72. Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87: 308-310.
73. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2929.
74. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61: 933-952.
75. Brugnara C, Chambers LA, Malynn E et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81: 956-964.
76. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
77. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S4-S8.
78. Steinmetz HT, Tsamaloukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010; 19: 261-269.
79. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 1994; 40: 768-773.
80. Xu Q, Zhu M, Yang T et al. Quantitative assessment of human serum transferrin receptor in breast cancer patients pre-and postchemotherapy using peptide immunoaffinity enrichment coupled with targeted proteomics. Clin Chim Acta 2015; 448: 118-123.
81. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
82. Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 mg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010; 85: 655-663.
83. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618.
84. Hedenus M, Birgegård G, Nasmän P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-632.
85. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
86. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26: 1619-1625.
87. Aapro M, Beguin Y, Birgegård G et al. Too-low iron doses and too many dropouts in negative iron trial? J Clin Oncol 2011; 29: e525-e526.
88. Steensma DP, Sloan JA, Dakhil SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29: 97-105.
89. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-525.
90. Kim YT, Kim SW, Yoon BS et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
91. Hedenus M, Karlsson T, Ludwig H et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 2014; 31: 302.
92. Steinmetz T, Tschechne B, Harlin O et al. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapyassociated anaemia. Ann Oncol 2013; 24: 475-482.
93. Toledano A, Luporsi E, Morere JF et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 2016; 24: 67-75.
94. Bailie GR, Hörl WH, Verhoef JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung 2011; 61: 267-275.
95. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines 2013; http://www. ema. europa. eu/docs/en-GB/document-library/Press-release/ 2013/06/WC500144874. pdf (22 February 2015, date last accessed).
96. Jaspers A, Baron F, Maertens J et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol 2015; 90: e133-e134.
97. Beguin Y, Aapro M, Ludwig H et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-a critical review. Crit Rev Oncol Hematol 2014; 89: 1-15.
98. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13: 342-355.
99. Kohgo Y, Ikuta K, Ohtake T et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15.
100. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003; 531: 81-92.
101. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S79-S86.
102. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001; 59: 140-148.
103. Rezazadeh H, Nayebi AR, Garjani A et al. Evidence that iron overload plus croton oil induce skin tumours in mice. Hum Exp Toxicol 2005; 24: 409-413.
104. Bergeron RJ, Streiff RR, Elliott GT. Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 1985; 115: 369-374.
105. Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 2013; 36: 266-272.
106. Ludwig H, Aapro M, Bokemeyer C et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 2014; 22: 2197-2206.
107. Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998; 15(Suppl 1): S47-S49.
108. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist 2011; 16(Suppl 3): 12-18.
109. Murphy GJ, Reeves BC, Rogers CA et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116: 2544-2552.
110. Isbister JP, Shander A, Spahn DR et al. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev 2011; 25: 89-101.
111. Baek JH, D'Agnillo F, Vallelian F et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 2012; 122: 1444-1458.
112. Upile T, Jerjes W, Mahil J et al. Blood product transfusion and cancer prognosis. Clin Adv Hematol Oncol 2009; 7: 656-661.
113. Al-Refaie WB, Parsons HM, Markin A et al. Blood transfusion and cancer surgery outcomes: a continued reason for concern. Surgery 2012; 152: 344-354.
114. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; 1: CD005033.
115. Bakkum-Gamez JN, Dowdy SC, Borah BJ et al. Predictors and costs of surgical site infections in patients with endometrial cancer. Gynecol Oncol 2013; 130: 100-106.
116. Halabi WJ, Jafari MD, Nguyen VQ et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg 2013; 206: 1024-1032.
117. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012; 4: CD002042.
118. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med 2014; 127: 124-131.
119. Rohde JM, Dimcheff DE, Blumberg N et al. Health care-associated infection after red blood cell transfusion: a systematic review and metaanalysis. JAMA 2014; 311: 1317-1326.
120. Holst LB, Petersen MW, Haase N et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ 2015; 350: h1354.
121. Carson JL, Hebert PC. Should we universally adopt a restrictive approach to blood transfusion? It's all about the number. Am J Med 2014; 127: 103-104.
122. Callum JL, Waters JH, Shaz BH et al. The AABB recommendations for the choosing wisely campaign of the American Board of Internal Medicine. Transfusion 2014; 54: 2344-2352.
123. Hicks LK, Bering H, Carson KR et al. The ASH Choosing WiselyVR campaign: five hematologic tests and treatments to question. Blood 2013; 122: 3879-3883.
124. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13-22.
125. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011; 16(Suppl 3): 3-11.
126. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg 2013; 116: 15-34.
127. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. Vasc Med 2011; 16: 119-130.
128. Hellström-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
129. Santini V, Schemenau J, Levis A et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 2013; 122: 2286-2288.
130. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology; Myelodysplastic Syndromes-v. 1. 2018, 2017; http://www. nccn. org/professionals/physician-gls/pdf/mds. pdf (18 October 2017, date last accessed).
131. Stauder R, Wimazal F, Nösslinger T et al. Individualized management and therapy of myelodysplastic syndromes. Wien Klin Wochenschr 2008; 120: 523-537.
132. Santini V, Alessandrino PE, Angelucci E et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010; 34: 1576-1588.
133. Moyo V, Lefebvre P, Duh MS et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008; 87: 527-536.
134. Mundle S, Lefebvre P, Vekeman F et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte-or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009; 115: 706-715.
135. Ross SD, Allen IE, Probst CA et al. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007; 12: 1264-1273.
136. Greenberg PL, Sun Z, Miller KB et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393-2400.
137. Jädersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-3613.
138. Park S, Grabar S, Kelaidi C et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and GCSF: the GFM experience. Blood 2008; 111: 574-582.
139. Smith SW, Sato M, Gore SD et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012; 97: 15-20.
140. Weise M, Bielsky MC, De Smet K et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-5117.
141. Weise M, Kurki P, Wolff-Holz E et al. Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-3196.
142. European Medicines Agency. Biosimilar medicines 2013; http://www. ema. europa. eu/ema/index. jsp?curl1/4pages/special-topics/document- listing/document-listing-000318. jsp (28 February 2015, date last accessed).
143. Brinks V, Hawe A, Basmeleh AH et al. Quality of original and biosimilar epoetin products. Pharm Res 2011; 28: 386-393.
144. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
145. Ferro HH, González EB. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2012; 81: 1273-1274.
146. Fotiou F, Aravind S, Wang PP et al. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 2009; 31: 336-346.
147. Wizemann V, Rutkowski B, Baldamus C et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008; 24: 625-637.
148. Krivoshiev S, Todorov VV, Manitius J et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24: 1407-1415.
149. Baldamus C, Krivoshiev S, Wolf-Pflugmann M et al. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008; 25: 1215-1228.
150. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009; 72: 380-390.
151. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Oncol Res Treat 2009; 32: 168-174.
152. Kerkhofs L, Boschetti G, Lugini A et al. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol 2012; 8: 751-756.
153. Barosi G, Bosi A, Abbracchio MP et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96: 937-942.
154. Lee ES, Park BR, Kim JS et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin 2013; 29: 141-147.
155. Martin-Malo A, Merino A, Carracedo J et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27: 2465-2471.
156. Rottembourg J, Kadri A, Leonard E et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011; 26: 3262-3267.
157. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012; 28: 241-243.
158. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 2012; 11: 66-78.
159. Borchard G, Flühmann B, Mühlebach S. Nanoparticle iron medicinal products-requirements for approval of intended copies of nonbiological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol 2012; 64: 324-328.
160. European Medicines Agency. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product 2015; http://www. ema. europa. eu/ema/pages/includes/document/open-document. jsp?web ContentId1/4WC500184922 (30 March 2015, date last accessed).
161. Ehmann F, Sakai-Kato K, Duncan R et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) 2013; 8: 849-856.
162. Schellekens H, Stegemann S, Weinstein V et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J 2014; 16: 15-21.
163. U. S. Food & Drug Administration. Information on erythropoiesisstimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp), 13 April 2017; https://www. fda. gov/Drugs/DrugSafety/ucm109375. htm (15 June 2017, date last accessed).
164. US Food & Drug Administration. FDA ODAC Briefing Document: BLA125545 "Epoetin Hospira", a proposed biosimilar to Epogen/ Procrit (epoetin alfa), 25 May 2017; https://www. fda. gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM559967. pdf (15 June 2017, date last accessed).
165. Jordan K, Feyer P, Höller U et al. Clinical practice guideline: supportive treatments for patients with cancer. Dtsch Arztebl Int 2017; 114: 481-487.